Glenmede Trust’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-2,297
| Closed | -$279K | – | 1438 |
|
|
2024
Q4 | $279K | Sell |
2,297
-41
| -2% | -$5.03K | ﹤0.01% | 1124 |
|
|
2024
Q3 | $292K | Buy |
2,338
+47
| +2% | +$6.5K | ﹤0.01% | 1099 |
|
|
2024
Q2 | $362K | Sell |
2,291
-342
| -13% | -$43.9K | ﹤0.01% | 1001 |
|
|
2024
Q1 | $341K | Buy |
2,633
+226
| +9% | +$27.7K | ﹤0.01% | 1021 |
|
|
2023
Q4 | $232K | Buy |
2,407
+93
| +4% | +$8.92K | ﹤0.01% | 1106 |
|
|
2023
Q3 | $281K | Buy |
2,314
+77
| +3% | +$8.7K | ﹤0.01% | 1017 |
|
|
2023
Q2 | $308K | Hold |
2,237
| – | – | ﹤0.01% | 983 |
|
|
2023
Q1 | $308K | Sell |
2,237
-4
| -0.2% | -$519 | ﹤0.01% | 988 |
|
|
2022
Q4 | $290K | Buy |
2,241
+33
| +1% | +$3.82K | ﹤0.01% | 995 |
|
|
2022
Q3 | $243K | Buy |
+2,208
| New | +$223K | ﹤0.01% | 1030 |
|
|
2021
Q1 | – | Sell |
-2,022
| Closed | -$343K | – | 1254 |
|
|
2020
Q4 | $343K | Sell |
2,022
-104
| -5% | -$15.4K | ﹤0.01% | 934 |
|
|
2020
Q3 | $297K | Sell |
2,126
-2
| -0.1% | -$304 | ﹤0.01% | 924 |
|
|
2020
Q2 | $340K | Buy |
2,128
+19
| +0.9% | +$2.59K | ﹤0.01% | 867 |
|
|
2020
Q1 | $272K | Hold |
2,109
| – | – | ﹤0.01% | 1083 |
|
|
2019
Q4 | $272K | Hold |
2,109
| – | – | ﹤0.01% | 1083 |
|
|
2019
Q3 | $158 | Sell |
2,109
-4
| -0.2% | -$472 | ﹤0.01% | 1255 |
|
|
2019
Q2 | $320 | Hold |
2,113
| – | – | ﹤0.01% | 1027 |
|
|
2019
Q1 | $251 | Buy |
2,113
+100
| +5% | +$12.9K | ﹤0.01% | 1098 |
|
|
2018
Q4 | $219 | Buy |
2,013
+13
| +0.7% | +$1.63K | ﹤0.01% | 1086 |
|
|
2018
Q3 | $323K | Hold |
2,000
| – | – | ﹤0.01% | 1002 |
|
|
2018
Q2 | $264K | Sell |
2,000
-300
| -13% | -$28.3K | ﹤0.01% | 985 |
|
|
2018
Q1 | $127K | Hold |
2,300
| – | – | ﹤0.01% | 1319 |
|
|
2017
Q4 | $127K | Buy |
2,300
+300
| +15% | +$15.9K | ﹤0.01% | 1319 |
|
|
2017
Q3 | $90K | Hold |
2,000
| – | – | ﹤0.01% | 1451 |
|
|
2017
Q2 | $59K | Hold |
2,000
| – | – | ﹤0.01% | 1541 |
|
|
2017
Q1 | $59K | Hold |
2,000
| – | – | ﹤0.01% | 1541 |
|
|
2016
Q4 | $54K | Sell |
2,000
-38
| -2% | -$1.53K | ﹤0.01% | 1583 |
|
|
2016
Q3 | $124K | Buy |
2,038
+38
| +2% | +$1.15K | ﹤0.01% | 1340 |
|
|
2016
Q2 | $38K | Hold |
2,000
| – | – | ﹤0.01% | 1670 |
|
|
2016
Q1 | $39K | Hold |
2,000
| – | – | ﹤0.01% | 1603 |
|
|
2015
Q4 | $77K | Hold |
2,000
| – | – | ﹤0.01% | 1434 |
|
|
2015
Q3 | $64K | Hold |
2,000
| – | – | ﹤0.01% | 1504 |
|
|
2015
Q2 | $60K | Sell |
2,000
-5,000
| -71% | -$102K | ﹤0.01% | 1571 |
|
|
2015
Q1 | $92K | Hold |
7,000
| – | – | ﹤0.01% | 1490 |
|
|
2014
Q4 | $101K | Buy |
7,000
+1,200
| +21% | +$20.3K | ﹤0.01% | 1528 |
|
|
2014
Q3 | $122K | Hold |
5,800
| – | – | ﹤0.01% | 1373 |
|
|
2014
Q2 | $172K | Hold |
5,800
| – | – | ﹤0.01% | 1224 |
|
|
2014
Q1 | $139K | Hold |
5,800
| – | – | ﹤0.01% | 1304 |
|
|
2013
Q4 | $118K | Buy |
5,800
+565
| +11% | +$16.8K | ﹤0.01% | 1344 |
|
|
2013
Q3 | $247K | Buy |
5,235
+235
| +5% | +$9.05K | ﹤0.01% | 1053 |
|
|
2013
Q2 | $190K | Buy |
+5,000
| New | +$179K | ﹤0.01% | 1096 |
|
Other funds holding SRPT
ACA
FCM
Glenmede Trust's SRPT Position: Q1 2025 in Review
Glenmede Trust sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 2,297 shares — an estimated $279K sold.
Glenmede Trust first reported a position in SRPT in Q2 2013 and held it in 41 quarters. The position peaked at $362K in Q2 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.
- Glenmede Trust reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
- Glenmede Trust sold 2,297 Sarepta Therapeutics shares in Q1 2025, an estimated $279K.
- Glenmede Trust first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 41 quarters.
- Glenmede Trust's Sarepta Therapeutics position peaked at $362K in Q2 2024.
- 430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.
Based on Glenmede Trust's 13F filing for Q1 2025, filed 15 May 2025.